Hodgkin Lymphoma
Pipeline by Development Stage
Drug Modality Breakdown
Hodgkin Lymphoma is a $6.1B market in mature consolidation, dominated by two mega-blockbusters but facing significant patent cliff pressure.
Key Trends
- Market heavily concentrated in immunomodulatory and ADC mechanisms with limited diversification
- Major patent cliff approaching in 2028 with REVLIMID ($3.9B) loss of exclusivity
- Strong pipeline activity with 461 trials suggests ongoing innovation despite mature indication
Career Verdict
Viable but consolidating: strong revenue base and hiring make it attractive, but approaching patent cliffs and limited primary indications create medium-term uncertainty.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | REVLIMID (lenalidomide) | Bristol Myers Squibb | $3.9B | 64% | LOE_APPROACHING | Declining | 1.8yr |
| 2 | ADCETRIS (brentuximab vedotin) | Pfizer | $3M | 0.05% | PEAK | Stable |
Drug Class Breakdown
approaching patent cliff 2028
secondary indication but stable
limited uptake as primary therapy
Career Outlook
StableHodgkin Lymphoma is a stable, mature market experiencing consolidation around two dominant players but actively hiring across all major functions. The approaching REVLIMID patent cliff in 2028 will create restructuring pressure and could accelerate M&A activity; professionals should expect transition roles and redeployment opportunities. Companies are investing in pipeline advancement (461 trials) to offset patent losses, creating near-term job security but long-term uncertainty.
Breaking In
Target commercial roles at Takeda or AstraZeneca for volume hiring; strong base salary and growth trajectory despite mature indication.
For Experienced Professionals
Experienced oncology professionals should position for pipeline leadership or transition roles; anticipate restructuring post-2028 patent cliff and consider diversifying expertise into emerging mechanisms (ADCs, bispecifics).
In-Demand Skills
Best For
Hiring Landscape
5,984 total positions available across Hodgkin Lymphoma indicate active hiring, with Commercial roles (1,019 positions) dominating and R&D (418 positions) showing solid growth. Takeda and AstraZeneca lead hiring, suggesting consolidation and pipeline advancement investments. Salary range spans $137K-$252K with commercial roles commanding premium compensation.
By Department
Commercial roles offer highest pay ($252K avg) and volume, making this attractive for field-based professionals; R&D salaries ($224K) competitive but lower volume.
On Market (2)
Approved therapies currently available
Competitive Landscape
19 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 50 trials with date data
Clinical Trials (50)
Total enrollment: 6,513 patients across 50 trials
A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India
PET Guided Dose Reduction for InvOlved Site Radiotherapy In Early sTage Unfavourable Hodgkin Lymphoma
FIL Study on ABVD DD-DI as Upfront Therapy in HL.
Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204)
ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas
A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma
Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Open Label Extension Study of Brentuximab Vedotin in Early dcSSc
PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma
Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)
Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides
Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression
Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas
A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma
Avelumab in the Frontline Treatment of Advanced Classical Hodgkin Lymphoma - a Window Study
Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma
Brentuximab Vedotin in Early Diffuse Cutaneous Systemic Sclerosis
Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma
Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17
BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
A Study of CS1001 in Subjects With Relapsed or Refractory Classical Hodgkin Lymphoma
Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)
Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas
A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma
Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma
Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087)
GHSG-AFM13 An Open-label, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma
Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL
Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia
Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma
Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)
Brentuximab Vedotin in the Elderly Hodgkin Lymphoma Patients at First Relapse or With Primary Refractory Disease.
Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma
Dose-dense ABVD First Line Therapy in Early Stage Unfavorable Hodgkin's Lymphoma
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma
A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma
Safety and Efficacy Study of PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma
A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies
A Multi-centre Study of MBVD in Elderly and/or Cardiopathic Patients Affected by Hodgkin's Lymphoma (HL)
Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study
Related Jobs in Oncology
Regional Medical Leader(MSL) (Oncology/Immuno-Oncology/GI)
Senior Oncology Sales Specialist
Senior Oncology Sales Specialist
Senior Oncology Sales Specialist
Senior Oncology Sales Specialist
Senior Oncology Sales Specialist
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.